Medical Devices Europe

Europe Companion Diagnostics Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Europe Companion Diagnostics Market Industry Trends and Forecast to 2034: Segmented by (Technology, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Europe · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $1.34 Bn Placeholder estimate
Estimate 2025 $1.47 Bn 17.1% of the global market
Projected 2034 $3.33 Bn 126.3% Adds $1.86 Bn over 9 forecast years
CAGR 2025–2034 9.5% Faster than 67% of 180 Medical Devices markets here
Key players 5
  • Europe is 17.07% of the global market.
  • Among regions, the largest is North America at $3.86 Bn.
  • Fastest growing: Africa at 12.8% a year.
  • Europe ranks 3rd of 6 by size among regions.

Market size projection

Europe

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.86 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Companion Diagnostics Market market size by year, Europe
YearMarket sizeChange that yearSince 2025
2024 (estimate) $1.34 Bn — —
2025 (base) $1.47 Bn +$127.7 Mn —
2026 (forecast) $1.61 Bn +$139.8 Mn +9.5%
2027 (forecast) $1.77 Bn +$153.1 Mn +19.9%
2028 (forecast) $1.93 Bn +$167.7 Mn +31.3%
2029 (forecast) $2.12 Bn +$183.6 Mn +43.8%
2030 (forecast) $2.32 Bn +$201.0 Mn +57.4%
2031 (forecast) $2.54 Bn +$220.1 Mn +72.4%
2032 (forecast) $2.78 Bn +$241.1 Mn +88.8%
2033 (forecast) $3.04 Bn +$264.0 Mn +106.7%
2034 (forecast) $3.33 Bn +$289.0 Mn +126.3%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Europe Companion Diagnostics Market Analysis at a glance
Market size, 2025$1.47 Bn placeholder estimate
Forecast, 2034$3.33 Bn placeholder estimate
Growth (CAGR), 2025–20349.5% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTechnology, indication and end user (see all)
Key playersRoche Diagnostics, Agilent Technologies, Qiagen N.V., Thermo Fisher Scientific Inc., Illumina, Inc. (see all)
Regulator in EuropeEU MDRSource: European Commission, medical devices. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Europe Companion Diagnostics Market Analysis Executive Summary

Companion diagnostics are tests that show whether a patient is likely to benefit from a specific medicine, often a cancer drug.

Key segments of the companion Diagnostics market include technology (Next-Generation Sequencing, PCR and Immunohistochemistry) and indication (Lung Cancer, Breast Cancer and Colorectal Cancer).

Bar chart: Europe Companion Diagnostics market size, 2024–2034, placeholder estimates. $1.34 Bn in 2024, $1.47 Bn in 2025 and $3.33 Bn in 2034, 9.5% CAGR.
Europe Companion Diagnostics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Europe Companion Diagnostics Market Dynamics

Market Growth Drivers

Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the companion Diagnostics market.

Opportunity

Home testing, connected devices that send results to doctors and multiplex tests that check many conditions at once give the companion Diagnostics market room to grow, especially in emerging markets.

Market Restraints

Pricing pressure, uneven reimbursement for new tests, regulatory approval times and the need for skilled lab staff hold back the companion Diagnostics market.

Competitive Landscape for Companion Diagnostics Market in Europe

The companion Diagnostics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Companion Diagnostics Market in Europe

Companion Diagnostics in Europe: rules and payment

In the EU, medical devices need CE marking under the Medical Device Regulation (MDR); for most devices, an independent notified body checks them first.⁠[1] In the countries we cover here, medical devices are regulated by ANSM (France)⁠[2], BfArM (Germany)⁠[3], Ministry of Health (Italy)⁠[4], Roszdravnadzor (Russia)⁠[5], AEMPS (Spain)⁠[6], MHRA (UK)⁠[7], IGJ (Netherlands)⁠[8], FAMHP (Belgium)⁠[9], Swissmedic (Switzerland)⁠[10], Läkemedelsverket (Sweden)⁠[11], Danish Medicines Agency (Denmark)⁠[12], URPL (Poland)⁠[13] and TITCK (Turkey)⁠[14]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.⁠[15]

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how companion Diagnostics products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Europe.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Companion Diagnostics right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Companion Diagnostics in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Companion Diagnostics market in Europe?
Placeholder estimate: about $1.47 Bn in 2025, rising to about $3.33 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Companion Diagnostics market in Europe growing?
Placeholder estimate: about 9.5% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Companion Diagnostics market report cover?
The report splits the market by technology (Next-Generation Sequencing, PCR, Immunohistochemistry, In Situ Hybridization), indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Blood Cancers) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Companion Diagnostics market?
Key players include Roche Diagnostics, Agilent Technologies, Qiagen N.V., Thermo Fisher Scientific Inc. and Illumina, Inc..
What is driving the Companion Diagnostics market?
Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the companion Diagnostics market.
Who regulates Companion Diagnostics in Europe?
In the EU, medical devices need CE marking under the Medical Device Regulation (MDR); for most devices, an independent notified body checks them first. Source: European Commission, medical devices. Checked 14 Nov 2026.
How is healthcare paid for in Europe?
Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines. Source: European Commission, health technology assessment. Checked 14 Nov 2026.
How much research is published on Companion Diagnostics?
PubMed lists 376 papers on Companion Diagnostics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in Europe

See all

Related on diagnostics and lab testing and oncology

See the topic